1. Prognostic Factors in Human Immunodeficiency Virus-Positive Patients with a CD4>= Lymphocyte Count <50/ L
- Author
-
Richard A. Kaslow, John P. Phair, Elizabeth G. Apolonio, Yanhua He, David W. Lyter, Alfred J. Saah, Donald R. Hoover, and Roger Detels
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multivariate analysis ,Adolescent ,Multicenter AIDS Cohort Study ,Acyclovir ,HIV Infections ,Cohort Studies ,Zidovudine ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Longitudinal Studies ,Homosexuality, Male ,Survival rate ,Performance status ,business.industry ,Middle Aged ,Prognosis ,CD4 Lymphocyte Count ,Survival Rate ,Clinical trial ,Infectious Diseases ,Multivariate Analysis ,Cohort ,Immunology ,HIV-1 ,Bisexuality ,business ,medicine.drug ,Cohort study - Abstract
This analysis investigated variability of survival time in a cohort of 553 human immunodeficiency virus type 1 (HIV-1)-infected homosexual or bisexual men with50 CD4+ cells/microL. Median survival after the first CD4+ cell count50/microL was 1.34 years; 25% survivedor = 2 years. Multivariate analysis showed longer survival with concurrent acyclovir and zidovudine use, hemoglobinor = 12 g/dL, and full-time employment (P.0001). Other significant covariates associated with longer survival included African-American race, no prior AIDS illness, weight loss4.5 kg, and zidovudine use (with or without concurrent acyclovir) after CD4+ cells fell to50/microL. An easily derived score identified Multicenter AIDS Cohort Study subjects likely to survive2 years after CD4+ cell count was50/microL. Survival once CD4+ cell count fell below 50/microL may be longer for persons with a good performance status and specific clinical markers. Health care providers should consider these variables in decision-making strategies and design of clinical trials.
- Published
- 1995